Proteins Regulating Microvesicle Biogenesis and Multidrug Resistance in Cancer

Taylor, J; Bebawy, M

Proteins Regulating Microvesicle Biogenesis and Multidrug Resistance in Cancer

Taylor, J Bebawy, M

Permalink

Publication Type:: Journal Article
Citation:: Proteomics, 2019, 19 (1-2)
Issue Date:: 2019-01-01

Closed Access

	Filename	Description	Size
	Taylor_et_al-2019-PROTEOMICS.pdf	Published Version	987.73 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Taylor, J	en_US
dc.contributor.author	Bebawy, M https://orcid.org/0000-0003-2606-921X	en_US
dc.date.issued	2019-01-01	en_US
dc.identifier.citation	Proteomics, 2019, 19 (1-2)	en_US
dc.identifier.issn	1615-9853	en_US
dc.identifier.uri	http://hdl.handle.net/10453/136314
dc.description.abstract	© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Microvesicles (MV) are emerging as important mediators of intercellular communication. While MVs are important signaling vectors for many physiological processes, they are also implicated in cancer pathology and progression. Cellular activation is perhaps the most widely reported initiator of MV biogenesis, however, the precise mechanism remains undefined. Uncovering the proteins involved in regulating MV biogenesis is of interest given their role in the dissemination of deleterious cancer traits. MVs shed from drug-resistant cancer cells transfer multidrug resistance (MDR) proteins to drug-sensitive cells and confer the MDR phenotype in a matter of hours. MDR is attributed to the overexpression of ABC transporters, primarily P-glycoprotein and MRP1. Their expression and functionality is dependent on a number of proteins. In particular, FERM domain proteins have been implicated in supporting the functionality of efflux transporters in drug-resistant cells and in recipient cells during intercellular transfer by vesicles. Herein, the most recent research on the proteins involved in MV biogenesis and in the dissemination of MV-mediated MDR are discussed. Attention is drawn to unanswered questions in the literature that may prove to be of benefit in ongoing efforts to improve clinical response to chemotherapy and circumventing MDR.	en_US
dc.relation.ispartof	Proteomics	en_US
dc.relation.isbasedon	10.1002/pmic.201800165	en_US
dc.subject.classification	Biochemistry & Molecular Biology	en_US
dc.title	Proteins Regulating Microvesicle Biogenesis and Multidrug Resistance in Cancer	en_US
dc.type	Journal Article
utslib.citation.volume	1-2	en_US
utslib.citation.volume	19	en_US
utslib.for	1112 Oncology and Carcinogenesis	en_US
utslib.for	0601 Biochemistry and Cell Biology	en_US
utslib.for	06 Biological Sciences	en_US
utslib.for	08 Information and Computing Sciences	en_US
utslib.for	11 Medical and Health Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	closed_access
pubs.issue	1-2	en_US
pubs.publication-status	Published	en_US
pubs.volume	19	en_US

Abstract:

© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Microvesicles (MV) are emerging as important mediators of intercellular communication. While MVs are important signaling vectors for many physiological processes, they are also implicated in cancer pathology and progression. Cellular activation is perhaps the most widely reported initiator of MV biogenesis, however, the precise mechanism remains undefined. Uncovering the proteins involved in regulating MV biogenesis is of interest given their role in the dissemination of deleterious cancer traits. MVs shed from drug-resistant cancer cells transfer multidrug resistance (MDR) proteins to drug-sensitive cells and confer the MDR phenotype in a matter of hours. MDR is attributed to the overexpression of ABC transporters, primarily P-glycoprotein and MRP1. Their expression and functionality is dependent on a number of proteins. In particular, FERM domain proteins have been implicated in supporting the functionality of efflux transporters in drug-resistant cells and in recipient cells during intercellular transfer by vesicles. Herein, the most recent research on the proteins involved in MV biogenesis and in the dissemination of MV-mediated MDR are discussed. Attention is drawn to unanswered questions in the literature that may prove to be of benefit in ongoing efforts to improve clinical response to chemotherapy and circumventing MDR.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/136314